Nobilis Therapeutics Inc.   Report issue

For profit Phase 3
Founded: Portland OR United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2018
NCT03635827
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Nobilis Therapeutics Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

xenon-129 (Xenoview) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Panic Disorder (Phase 3)

Parkinson Disease (Phase 1)

Stress Disorders, Post-Traumatic (Phase 3)

Stress Disorders, Traumatic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1